文献速递淋巴瘤

CAR-T与双特异性抗体治疗复发难治性滤泡性淋巴瘤的生存与时间毒性比较

Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL.
PubMed 文献 · Blood Adv · 2026-10-30

这项多中心回顾性研究纳入228例三线及以上复发难治性滤泡性淋巴瘤患者,比较CAR-T(141例)与CD20xCD3双特异性抗体(87例)的真实世界结局。CAR-T组无进展生存期显著优于双特异性抗体组,但总生存期无差异,且CAR-T组第一年时间毒性更高(门诊接触天数更多)。

要点

  • CAR-T组无进展生存期显著优于双特异性抗体组,二线后及三线后亚组均一致。
  • 两组总生存期无显著差异。
  • CAR-T组第一年时间毒性更高,平均接触天数更多。

核心结论

  • 在复发难治性滤泡性淋巴瘤中,CAR-T相比双特异性抗体与更优的无进展生存期相关,但时间毒性更高。

研究设计与样本

  • 多中心回顾性研究,纳入17家美国学术中心228例三线及以上复发难治性滤泡性淋巴瘤患者,CAR-T组141例,双特异性抗体组87例。

主要发现

  • 二线后队列中,CAR-T组中位无进展生存期未达到,双特异性抗体组为581天(p < .0001)。
  • 三线后队列中,CAR-T组中位无进展生存期未达到,双特异性抗体组为584天(p = .0064)。
  • 两组总生存期无差异。
  • 第一年平均接触天数:二线后队列CAR-T组58天 vs 双特异性抗体组44天;三线后队列CAR-T组69天 vs 双特异性抗体组49天。

临床怎么用

  • CAR-T的无进展生存期优势独立于年龄、体能状态和既往治疗难治性差异。
  • 时间毒性数据可为复发难治性滤泡性淋巴瘤的治疗排序决策提供参考。

局限性

  • 回顾性研究设计。
  • CAR-T组患者更年轻、体能状态更好但既往治疗更难治,存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T-cell (CAR-T) and CD20xCD3 bispecific antibody (BsAb) therapies are both effective for relapsed/refractory (R/R) follicular lymphoma (FL), but comparative real-world survival outcomes and time toxicity have not been characterized. We performed a multicenter retrospective study of 228 patients with R/R FL treated with standard-of-care CAR-T (n = 141) or BsAb (n = 87) across 17 U.S. academic centers in the third-line or later setting. Progression-free survival (PFS) and overall survival (OS) were stratified by 2 or ≥3 prior lines of therapy (LOT2 or LOT3+), including propensity matching. Time toxicity was measured by physical health care contact days. Median PFS was not reached (NR) with CAR-T and 581 days with BsAb in the LOT2 cohort (p < .0001), and was NR with CAR-T and 584 days with BsAb in the LOT3+ cohort (p = .0064). CAR-T recipients were younger (p < .0001) and had better performance status (p = .007) but were more refractory to prior LOT (p = .017). PFS advantages of CAR-T were independent of these differences. OS did not differ between treatment groups. CAR-T had significantly greater time toxicity over the first year, with higher mean contact days than BsAb in both the LOT2 (58 vs 44) and LOT3+ (69 vs 49) cohorts. In this large multicenter cohort of patients with R/R FL, CAR-T was associated with superior PFS but greater time toxicity compared with BsAb therapy. These findings provide real-world outcomes data and time toxicity benchmarks to support treatment sequencing decision-making in R/R FL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Major A, Abbott D, Snyder J, et al. Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL. Blood Adv. 2026. PMID: 42962270. doi:10.1182/bloodadvances.2026020899

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。